Market Closed -
Nasdaq
04:30:01 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.7285
USD
|
-2.84%
|
|
+1.48%
|
-42.64%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15.56
|
7.761
|
11.95
|
2.108
|
6.082
|
3.748
|
-
|
-
|
Enterprise Value (EV)
1 |
15.56
|
7.761
|
11.95
|
2.108
|
6.082
|
3.748
|
3.748
|
3.748
|
P/E ratio
|
-1.43
x
|
-0.62
x
|
-1.32
x
|
-0.2
x
|
-0.11
x
|
-1.1
x
|
-1.66
x
|
-1.87
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
109
x
|
27.5
x
|
19.9
x
|
-
|
5.1
x
|
1.66
x
|
0.83
x
|
0.46
x
|
EV / Revenue
|
109
x
|
27.5
x
|
19.9
x
|
-
|
5.1
x
|
1.66
x
|
0.83
x
|
0.46
x
|
EV / EBITDA
|
-
|
-1.13
x
|
-1.52
x
|
-
|
-0.88
x
|
-0.78
x
|
-0.84
x
|
-1.16
x
|
EV / FCF
|
-
|
-1.07
x
|
-
|
-
|
-
|
-0.55
x
|
-0.67
x
|
-0.92
x
|
FCF Yield
|
-
|
-93.1%
|
-
|
-
|
-
|
-182%
|
-150%
|
-109%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
5.89
|
18.7
|
50.9
|
56.8
|
4,789
|
5,145
|
-
|
-
|
Reference price
2 |
2,640
|
414.0
|
234.9
|
37.08
|
1.270
|
0.7285
|
0.7285
|
0.7285
|
Announcement Date
|
3/16/20
|
3/25/21
|
3/29/22
|
3/16/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.143
|
0.282
|
0.6
|
-
|
1.193
|
2.254
|
4.508
|
8.114
|
EBITDA
1 |
-
|
-6.881
|
-7.841
|
-
|
-6.922
|
-4.824
|
-4.468
|
-3.244
|
EBIT
1 |
-10.29
|
-7.933
|
-8.934
|
-
|
-7.732
|
-6.006
|
-5.698
|
-4.531
|
Operating Margin
|
-7,193.71%
|
-2,813.12%
|
-1,489%
|
-
|
-648.11%
|
-266.46%
|
-126.4%
|
-55.84%
|
Earnings before Tax (EBT)
1 |
-10.02
|
-7.937
|
-8.268
|
-
|
-7.71
|
-6.589
|
-6.678
|
-5.93
|
Net income
1 |
-10.03
|
-8.373
|
-8.268
|
-9.695
|
-7.71
|
-6.589
|
-6.678
|
-5.93
|
Net margin
|
-7,013.29%
|
-2,969.15%
|
-1,378%
|
-
|
-646.27%
|
-292.32%
|
-148.14%
|
-73.08%
|
EPS
2 |
-1,846
|
-667.2
|
-177.6
|
-186.0
|
-11.51
|
-0.6600
|
-0.4400
|
-0.3900
|
Free Cash Flow
1 |
-
|
-7.222
|
-
|
-
|
-
|
-6.835
|
-5.612
|
-4.082
|
FCF margin
|
-
|
-2,560.99%
|
-
|
-
|
-
|
-303.24%
|
-124.49%
|
-50.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/25/21
|
3/29/22
|
3/16/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.183
|
0.169
|
0.195
|
0.277
|
0.25
|
0.233
|
0.305
|
0.36
|
0.295
|
0.429
|
0.485
|
0.582
|
0.757
|
EBITDA
1 |
-1.961
|
-2.165
|
-2.043
|
-2.277
|
-2.501
|
-1.843
|
-1.678
|
-1.746
|
-1.617
|
-1.397
|
-1.303
|
-1.158
|
-0.966
|
EBIT
1 |
-2.253
|
-2.493
|
-2.333
|
-2.572
|
-2.619
|
-2.045
|
-2
|
-1.951
|
-1.736
|
-1.683
|
-1.596
|
-1.458
|
-1.27
|
Operating Margin
|
-1,231.15%
|
-1,475.15%
|
-1,196.41%
|
-928.52%
|
-1,047.6%
|
-877.68%
|
-655.74%
|
-541.94%
|
-588.47%
|
-392.31%
|
-329.07%
|
-250.52%
|
-167.77%
|
Earnings before Tax (EBT)
1 |
-2.253
|
-2.494
|
-2.332
|
-2.569
|
-2.646
|
-2.037
|
-1.993
|
-1.947
|
-1.733
|
-1.743
|
-1.741
|
-1.632
|
-1.473
|
Net income
1 |
-2.253
|
-2.494
|
-2.332
|
-2.569
|
-2.646
|
-2.037
|
-1.993
|
-1.947
|
-1.733
|
-1.743
|
-1.741
|
-1.632
|
-1.473
|
Net margin
|
-1,231.15%
|
-1,475.74%
|
-1,195.9%
|
-927.44%
|
-1,058.4%
|
-874.25%
|
-653.44%
|
-540.83%
|
-587.46%
|
-406.29%
|
-358.97%
|
-280.41%
|
-194.58%
|
EPS
2 |
-43.20
|
-50.40
|
-45.60
|
-50.40
|
-52.80
|
-15.84
|
-8.400
|
-5.640
|
-9.540
|
-0.3400
|
-0.1100
|
-0.1100
|
-0.1000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/29/22
|
5/12/22
|
8/11/22
|
11/14/22
|
5/11/23
|
8/10/23
|
11/9/23
|
2/21/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-7.22
|
-
|
-
|
-
|
-6.84
|
-5.61
|
-4.08
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.11
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
40.43%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/25/21
|
3/29/22
|
3/16/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
0.7285
USD Average target price
3.5
USD Spread / Average Target +380.44% Consensus |
1st Jan change
|
Capi.
|
---|
| -42.64% | 3.75M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|